Goldman Sachs analyst, Paul Choi, reiterated his Neutral rating on Aimmune Therapeutics (NASDAQ: AIMT) but raised his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE